THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
대리인 / 주소
Cantor Colburn LLP
인용정보
피인용 횟수 :
0인용 특허 :
22
초록▼
Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhi
Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.
대표청구항▼
1. A compound according to formula IX, wherein each R1 is independently hydroxyl, C1-10alkoxy, or C1-10alkyl ester; R2, and R4 independently are halogen; R5 is independently hydrogen, hydroxy, or halogen; and R9, R10, and R11 independently are hydrogen, hydroxyl, C1-10 alkoxy, or —B(OH)2. 2. The co
1. A compound according to formula IX, wherein each R1 is independently hydroxyl, C1-10alkoxy, or C1-10alkyl ester; R2, and R4 independently are halogen; R5 is independently hydrogen, hydroxy, or halogen; and R9, R10, and R11 independently are hydrogen, hydroxyl, C1-10 alkoxy, or —B(OH)2. 2. The compound of claim 1, wherein the compound has formula IX, and wherein each R1 is hydroxyl or methoxy, R2 and R4 independently are halogen, R5 is hydrogen or halogen, and at least one of R9, R10, and R11 is hydrogen. 3. The compound of claim 1, wherein the compound has the formula 4. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the pharmaceutical composition is capable of inhibiting bacterial cell growth when applied to a bacterium. 5. The pharmaceutical composition of claim 4, further comprising a therapeutically effective amount of a second agent other than the compound. 6. The pharmaceutical composition of claim 5, wherein the second agent is an antimicrobial agent. 7. The pharmaceutical compound of claim 6, wherein the second agent is effective against Gram-negative bacterial cells. 8. The pharmaceutical composition of claim 5, wherein the second agent increases penetration of the compound into the bacterium. 9. A method of inhibiting bacterial cell growth, comprising exposing a bacterium to an effective amount of a composition comprising a compound of claim 3 or pharmaceutical acceptable salt, hydrate, or solvate thereof, wherein the bacterium is Staphylococcus aureus, Bacillus subtilis, Escherichia coli, envelop-deficient Escherichia coli, methicillin-resistant Staphylococcus aureus, multidrug-resistant Staphylococcus aureus, or vancomycin-resistant Enterococcus faecium. 10. The method of claim 9, further comprising exposing the bacterium to an effective amount of a second agent other than the compound. 11. The method of claim 10, wherein the second agent is included in the composition. 12. The method of claim 10 or claim 11, wherein the second agent is an antimicrobial agent. 13. The method of claim 12, wherein the antimicrobial agent is effective against Gram-negative bacterial cells. 14. The method of claim 10 or 11, wherein the second agent increases penetration of the compound into the bacterium. 15. The method of claim 9, wherein exposing the bacterium to an effective amount of the composition comprises administering a therapeutically effective amount of the composition to a subject identified as being in need of antimicrobial treatment for a known or suspected bacterial infection. 16. The method of claim 15, wherein the second agent is not included in the composition, and the second agent is administered separately to the subject. 17. The method of claim 15 or claim 16, further comprising identifying the subject as being infected with a bacterium that is susceptible to treatment with the compound before administering the composition to the subject.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (22)
DeVore Dale P. ; Eiferman Richard A. ; Keates Edwin U., Compound delivery using rapidly dissolving collagen film.
Fallon Renee A. (Sunnyvale CA) Wilson Donald R. (San Francisco CA), Device for administering drug transdermally which provides an initial pulse of drug.
Bawa Rajan ; Hall Rex E. ; Kabra Bhagwati P. ; Teague James E. ; Cagle Gerald D. ; Markwardt Kerry L. ; Shah Mandar V., Gelling ophthalmic compositions containing xanthan gum.
Valdivia Francisco Javier Galan (Barcelona ESX) Dachs Anna Coll (Barcelona ESX) Perdiguer Nuria Carreras (Caldes de Montbui ESX), Nanoemulsion of the oil water type, useful as an ophthalmic vehicle and process for the preparation thereof.
Tucker Mark J. (Round Steps ; High Street Stow-on-the-Wold ; Gloucester GL54 1DL GBX) Tucker Mark R. (P.O. Box 23530 Bahrain BHX), Occlusive body for administering a physiologically active substance.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Ann Arbor MI) Henry Raymond L. (Grosse Pointe Woods MI), Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide.
Farhadieh Bahram (Libertyville IL) Gokhale Rajeev D. (Vernon Hills IL) Berger Hana (Lincolnshire IL) Vallner Joseph (Mountainview CA), Single layer transdermal drug administration system.
Lang John C. (Arlington TX) Keister Jamieson C. (Crowley TX) Missel Paul J. T. (Arlington TX) Stancioff Dimitri J. (Camden ME), Use of carrageenans in topical ophthalmic compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.